Högskolan i Skövde

his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clinical Outcome 3 Years After Autologous Chondrocyte Implantation Does Not Correlate With the Expression of a Predefined Gene Marker Set in Chondrocytes Prior to Implantation but Is Associated With Critical Signaling Pathways
Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Department of Orthopaedics, University Medical Center Utrecht, Utrecht, the Netherlands.
University of Skövde, School of Bioscience. University of Skövde, The Systems Biology Research Centre. (Bioinformatics)ORCID iD: 0000-0003-4697-0590
Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Show others and affiliations
2014 (English)In: The Orthopaedic Journal of Sports Medicine, ISSN 2325-9671, Vol. 2, no 9, p. 1-14, article id 2325967114550781Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: There is a need for tools to predict the chondrogenic potency of autologous cells for cartilage repair.

PURPOSE: To evaluate previously proposed chondrogenic biomarkers and to identify new biomarkers in the chondrocyte transcriptome capable of predicting clinical success or failure after autologous chondrocyte implantation.

STUDY DESIGN: Controlled laboratory study and case-control study; Level of evidence, 3.

METHODS: Five patients with clinical improvement after autologous chondrocyte implantation and 5 patients with graft failures 3 years after implantation were included. Surplus chondrocytes from the transplantation were frozen for each patient. Each chondrocyte sample was subsequently thawed at the same time point and cultured for 1 cell doubling, prior to RNA purification and global microarray analysis. The expression profiles of a set of predefined marker genes (ie, collagen type II α1 [COL2A1], bone morphogenic protein 2 [BMP2], fibroblast growth factor receptor 3 [FGFR3], aggrecan [ACAN], CD44, and activin receptor-like kinase receptor 1 [ACVRL1]) were also evaluated.

RESULTS: No significant difference in expression of the predefined marker set was observed between the success and failure groups. Thirty-nine genes were found to be induced, and 38 genes were found to be repressed between the 2 groups prior to autologous chondrocyte implantation, which have implications for cell-regulating pathways (eg, apoptosis, interleukin signaling, and β-catenin regulation).

CONCLUSION: No expressional differences that predict clinical outcome could be found in the present study, which may have implications for quality control assessments of autologous chondrocyte implantation. The subtle difference in gene expression regulation found between the 2 groups may strengthen the basis for further research, aiming at reliable biomarkers and quality control for tissue engineering in cartilage repair.

CLINICAL RELEVANCE: The present study shows the possible limitations of using gene expression before transplantation to predict the chondrogenic and thus clinical potency of the cells. This result is especially important as the chondrogenic potential of the chondrocytes is currently part of quality control measures according to European and American legislations regarding advanced therapies.

Place, publisher, year, edition, pages
Sage Publications, 2014. Vol. 2, no 9, p. 1-14, article id 2325967114550781
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Research subject
Bioinformatics
Identifiers
URN: urn:nbn:se:his:diva-12037DOI: 10.1177/2325967114550781PubMedID: 26535366Scopus ID: 2-s2.0-84979085388OAI: oai:DiVA.org:his-12037DiVA, id: diva2:911922
Note

CC BY-NC-ND 3.0

Available from: 2016-03-14 Created: 2016-03-14 Last updated: 2022-05-06Bibliographically approved

Open Access in DiVA

fulltext(1305 kB)143 downloads
File information
File name FULLTEXT01.pdfFile size 1305 kBChecksum SHA-512
8ffba2e9678c2a9c5c8ac126c7a5936a9c3ec65ce7e85a5af94d8ac0040201d738f4734b9e1223427e8b3ee21e6cc54fae0259efa761baab4d8b4385887284b4
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Synnergren, Jane

Search in DiVA

By author/editor
Synnergren, Jane
By organisation
School of BioscienceThe Systems Biology Research Centre
In the same journal
The Orthopaedic Journal of Sports Medicine
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar
Total: 143 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 739 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf